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York, YO10 5DD, UKPost kala-azar dermal leishmaniasis (PKDL), a cutaneous
sequela of visceral leishmaniasis (VL), develops in some
patients alongside but more commonly after apparent
cure from VL. In view of the pivotal role of PKDL patients
in the transmission of VL, here we review clinical, epi-
demiological, parasitological, and immunological per-
spectives of this disease, focusing on five hypotheses
to explain the development of PKDL: (i) the role of
antimonial drugs; (ii) UV-induced skin damage; (iii) rein-
fection; (iv) organ specific failure of memory T cell
responses; and (v) genetic susceptibility of the host. This
review will enable researchers and clinicians to explore
the unresolved mystery of PKDL and provide a frame-
work for future application of ‘omic’ approaches for the
control and eventual elimination of VL.
PKDL: current scenario
The leishmaniases comprise a diverse group of poverty-
related neglected tropical diseases that have a major im-
pact on health worldwide. Among the manifestations of
leishmaniasis, post kala-azar dermal leishmaniasis
(PKDL; see Glossary) caused by the protozoan parasite
Leishmania donovani, is possibly the most intriguing clin-
ically and scientifically, as it generally develops as a se-
quela after apparent successful cure from visceral
leishmaniasis (VL; also known as kala-azar) [1,2]. The
clinical presentation of VL and PKDL differ substantially;
in VL, patients suffer from prolonged fever, hepatospleno-
megaly, weight loss, and anaemia, whereasmanifestations
of PKDL are limited tomacular, papular, or nodular lesions
in the skin [2]. PKDL is confined to two geographically
distinct zones, namely South Asia (India, Nepal, and
Bangladesh) and East Africa, mainly Sudan [2,3]. In the
South Asian variant, polymorphic lesions (coexistence of
macules/patches along with papulonodules) are prevalent,1471-4922/$ – see front matter
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lesions. Although mortality from PKDL is low, it is a stig-
matizing disease that carries a significant socioeconomic
burden, further amplified by a reluctance to obtain treat-
ment or due to noncompliance. Lesions, especially the papu-
lonodules, are parasite-rich, driving speculation that PKDL
playsapivotal role in the inter-epidemic transmissionofVL.
Understanding the clinico-epidemiological aspects of
PKDL would help define strategies for controlling VL, by
providing further insights into L. donovani transmission
dynamics. Most epidemiological studies with PKDL have
reported no gender bias [4–8], a notable exception being
studies from our group where a male predominance was
reported [9]. The age distribution of PKDL in South Asia
and Sudan also differs, as in the former, young adults are
more affected whereas in the latter, children are more
affected [4]. A lag period ranging from 2 to 10 years exists
between cure from VL and onset of PKDL, suggesting that
PKDL echoes the epidemic of VL and can persist well after
the epidemic. This is supported by an epidemiological
study in Bangladesh where it was noted that the incidence
of PKDL showed a steep rise from 1 case per 10 000 in
2002–2004 to 21 cases per 10 000 in 2007 [6]. In India, the
incidence of VL peaked in 1992 and a smaller rise was
reported in 2007 (http://www.who.int/leishmaniasis/
resources/INDIA.pdf). Therefore, extrapolating from the
Bangladesh experience, the incidence of PKDL in India
may well see a sharp rise in coming years. In South Asia,
transmission of VL is anthroponotic, whereas in Sudan, it
is zoonotic and anthroponotic; therefore, patients with
PKDL are the proposed disease reservoir of VL in India
[10]. Accordingly, eradication of PKDL should be an essen-
tial component of the current VL elimination programme
in South Asia that aims to bring down the annual incidence
of VL to less than 1 per 10 000 population at a district or
sub-district level by the end of 2015 (http://www.who.int/
tdr/publications/documents/kala_azar_indicators.pdf). To
achieve this goal, a greater understanding of the cause(s)
of PKDL is essential. Many excellent reviews have covered
the epidemiology, immunopathology, diagnosis, and treat-
ment of PKDL; Box 1 and Figure 1 summarise our current
knowledge of the immune responses observed in PKDL
[2,4,11–14]. Information regarding the aetiopathogenesis
of PKDL is limited and, therefore, no consensus has
emerged to explain what factors modify the behaviour of
the normally viscerotropic L. donovani parasite to becomeTrends in Parasitology, February 2014, Vol. 30, No. 2 65
Glossary
Amastigote antigen 2 (A2): an amastigote stage specific protein of Leishmania
that plays a role in its survival within the mammalian host. It is induced by
stress, and following heat shock it complexes with endoplasmic reticulum
binding protein, BiP. By contrast, the A2 gene in L. major is a non-expressed
pseudogene. A2 may also play a role in protecting L. donovani from stress
associated with infection involving visceral organs, including fever typically
associated with visceral leishmaniasis.
Amphotericin B: a polyene antifungal drug, often used intravenously for
systemic fungal and parasitic infections including leishmaniasis; binds with
ergosterol, a component of fungal and protozoal cell membranes, forms a
transmembrane channel that leads to cell leakage and death.
Anthroponotic: an infectious disease caused by microorganisms that normally
exist in a transmission cycle involving only humans, for example, tuberculosis
and malaria.
CD25: the IL-2 receptor a chain present on activated T cells, B cells, natural
killer (NK) cells, and monocytes. Additionally, CD25 along with FoxP3 is
considered as one of the potent markers of T regulatory cells.
CD80 (or B7.1): is found on the surface of activated B cells and monocytes and
provides the dominant co-stimulatory pathways that regulate T and B cell
responses. It can bind to either CD28 to provide a stimulatory signal to T cells
or can combine with cytotoxic T lymphocyte antigen 4 (CTLA-4) to send a
negative signal to T cells.
CD86 (or B7.2): is a protein expressed on antigen-presenting cells that provide
co-stimulatory signals necessary for T cell activation and survival.
Clinical cure: the disappearance of all clinical signs and symptoms, but does
not necessarily mean complete elimination of the causative organism. On the
contrary, sterile cure or radical cure is complete elimination of the causative
organism. Occasionally, clinical cure is associated with the presence of the
organism in a site other than the disease site, for example, leishmaniasis and
malaria.
C-reactive protein (CRP): a protein found in blood, which increases in response
to inflammation; it is considered as an acute-phase protein, that is, serum
molecules that increase rapidly at the onset of infection.
Cutaneous leishmaniasis (CL): a tropical infection caused by vector-borne
protozoa of the Leishmania species. It is often referred to as a group of
diseases because of the varied spectrum of clinical manifestations, which
range from small cutaneous nodules to gross mucosal tissue destruction. The
disease is rarely fatal and can be subdivided into ‘self-healing’ or ‘non-self-
healing’ forms.
Cutaneous T cell antigen (CLA): a unique skin-homing receptor expressed by
memory T cells that infiltrate the skin; facilitates targeting of T cells to inflamed
skin.
Cytochrome p450 27B1 (CYP27B1): a cytochrome P450 enzyme, also known as
5-hydroxyvitamin D3 1-a-hydroxylase, located on the inner mitochondrial
membrane. It catalyses hydroxylation of 25-hydroxyvitamin D3 at the 1-a
position to synthesise 1-a, 25-dihydroxyvitamin D3, the active form of vitamin
D3, which then binds to the vitamin D receptor and regulates calcium
metabolism.
Dermatotropic: a higher affinity for the skin.
Epidermal Langerhans cells (E-LCs): Langerin (a Ca2+-dependent lectin
receptor, CD207) positive dendritic cells that reside within the epidermis and
act as major antigen-presenting cells during skin infections.
Ficolin-2: secreted pattern recognition lectins that contribute to the innate
immune recognition of pathogens and activate the complement pathway to
clear pathogens.
Forkhead box P3 (FoxP3): is also known as scurfin, and it is the master
regulator as well as transcription factor of T regulatory cells. It inhibits the
transcription of IFN-g and activates transcription of IL-10.
Glutathione (GSH): a tripeptide (g-glutamyl-cysteinyl-glycine) and the most
abundant low molecular weight thiol in cells. It plays an important role in
oxidation reduction reactions because GSH with glutathione peroxidase
scavenges toxic hydrogen peroxide.
Glycoprotein 63 (gp63): a major surface glycoprotein of the genus Leishmania
and is considered a major virulence factor of the parasite. Functionally, it is a
surface Zn metalloprotease, and it has the ability to modulate macrophage
signalling pathways.
Hapten-induced contact-dependent hypersensitivity: a Langerhans cell
mediated CD8+ T cell dependent immune response elicited by epicutaneous
sensitisation with haptens (i.e., chemicals including metals). Such reactions in
mice and humans are mediated by Th1 or T cytotoxic 1 (Tc1) effector cells and
downregulated by Th2 or T regulatory CD4+ T cells. The response develops in two
distinct phases: (i) a sensitisation phase where the haptens penetrating the skin
are captured by resident dendritic cells, which migrate to regional lymph nodes
and induce activation of specific T cell precursors; (ii) the elicitation phase, which
is induced by re-exposure to the same hapten at a remote skin site. Within a few
hours, this leads to the rapid recruitment and activation of specific T cells and a
local inflammatory response, which peaks at 24–48 h after challenge.
Haem oxygenase 1: an essential enzyme in haem catabolism that cleaves haem
to form biliverdin and carbon monoxide. Haem oxygenase has two isoforms:
haem oxygenase 1, which is inducible, whereas haem oxygenase 2 is
constitutive in nature. Haem oxygenase-derived carbon monoxide and
biliverdin have potent anti-inflammatory activity and can suppress macro-
phage function.
Human cathelicidin (hCAP-18): cathelicidins are a family of antimicrobial
proteins among which hCAP-18 liberates the antibacterial, cytotoxic peptide
LL-37.
Interferon-g (IFN-g): a cytokine produced primarily by T lymphocytes and NK
cells. It induces the production of an array of cytokines and upregulates the
expression of class I and class II MHC antigens, Fc receptor, and leukocyte
adhesion molecules. It modulates macrophage effector functions, influences
isotype switching, and potentiates the secretion of immunoglobulins by B cells.
IFN-g also augments helper T cell expansion andmay be required for helper T cell
differentiation. IFN-gR is expressed at moderate levels on virtually every cell with
the exception of erythrocytes. Upon binding to IFN-g, the receptor dimerises and
activates transcription factors, resulting in increased production of proinflam-
matory molecules. Polymorphism in IFN-gR contributes to its lowered function
and subsequently influences the cellular responsiveness towards IFN-g.
Interleukin 10 (IL-10): an important immunoregulatory cytokine produced by
many cell populations. Its main biological function seems to be the limitation
and termination of inflammatory responses and the regulation of differentia-
tion and proliferation of several immune cells such as T cells, B cells, NK cells,
antigen-presenting cells, etc. Antigen-presenting cells and lymphocytes are the
primary targets of IL-10 by its ability to regulate the Th1/Th2 balance. IL-10
promotes the development of a Th2 immune pattern by inhibiting the IFN-g
production of T lymphocytes, particularly via the suppression of IL-12
synthesis in macrophages. IL-10 is also secreted from T regulatory cells to
counter balance inflammation.
Kala-azar: an alternative name for visceral leishmaniasis. The name originated
from two words, kala (means black) and azar (means fever), attributed to the
association of fever with hypopigmentation.
Keratinisation: a biochemical process of keratin deposition on cells. During this
process, the epidermis sheds dead skin cells.
Major histocompatibility complex class II (MHCII) genes: MHCII genes encode
peptide transporters expressed by antigen-presenting cells (macrophages,
dendritic cells, B cells) that facilitate recognition of antigenic peptides by T
cells; in humans, the MHCII genes are HLA-DR, HLA-DP, and HLA-
DQ. Expression of MHCII genes is upregulated upon exposure to IFN-g and
inhibited by exposure to IL-10.
Mannose-binding lectin 2 (MBL-2): belongs to the collectin protein family and
is an important element in the innate immune system. MBL-2 recognises
mannose and N-acetylglucosamine on many microorganisms and is capable of
activating the classical complement pathway.
Miltefosine (hexadecylphosphocholine): the first oral drug used for treatment
of leishmaniasis. Miltefosine belongs to the class of alkylphosphocholine
drugs, which are phosphocholine esters of aliphatic long-chain alcohols. The
dosage for treatment of VL is based on the patient’s body weight (b.w.):
100 mg/day (28 days) for b.w. >25 kg and 50 mg/day (28 days) for b.w. <25 kg.
For the treatment of PKDL, the same dose has been used but the duration
increased to 12 weeks. Miltefosine has a dual effect on leishmaniasis because it
causes mitochondrial dysfunction, inhibition of cytochrome C oxidase, and
increased generation of reactive oxygen species resulting in an apoptotic-like
death in Leishmania parasites; in parallel, it raises the proinflammatory
cytokines and molecules in Leishmania-infected macrophages and in patients
with human leishmaniasis.
Papulonodules: a papule is a circumscribed, solid elevation of skin with no
visible fluid and indurations, whereas nodules are larger solid areas of skin,
with more than 0.5 cm area and indurations. Patients who have both papules
and nodules are considered as papulonodules.
Parasite persistence: the presence of parasites even after clinical cure. It is
generally seen in tryponosomasis and leishmaniasis.
Paromomycin: an aminoglycoside antibiotic isolated from Streptomyces
krestomuceticus used for the treatment of VL.
Photoisomerisation: the light-initiated process of change from one isomeric
form of a compound, radical, or ion to another. Importantly, in this process the
changing in shape occurs without breakage of chemical bonding, an example
being conversion of 11 cis retinal to conversion into all-trans by photons.
Post kala-azar dermal leishmaniasis (PKDL): a chronic, dermal sequel of VL or
kala-azar that occurs in some but not all who are treated for kala-azar. PKDL is
confined mainly to India and its adjoining countries, such as Bangladesh and
Nepal, and it is also seen in Sudan and Kenya. Clinically, the disease is
characterised by a macular, depigmented eruption found mainly on the face,
arms, and upper part of the trunk.
Promastigote surface antigen 2 (PSA2): a surface glycoprotein of Leishmania
expressed on both promastigotes and amastigotes. It has been proposed to be
involved in host–parasite physical interactions. It plays a role in parasite
attachment through complement receptor 3 (CR3) and is associated with the
resistance against complement-mediated lysis. PSA2 is an immunologically
reactive protein that induces high levels of Th1 cytokines and is therefore
considered as a vaccine candidate.
Self-limiting PKDL: in Sudan, spontaneous healing frequently occurs in
patients with PKDL, and is considered as self-limiting PKDL. In these patients,
the lesions regress spontaneously with or without leaving scars.
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Sodium antimony gluconate (SAG): a pentavalent antimonial that was the
drug of choice for treatment of kala-azar or VL. After being converted into the
trivalent form, it enters into macrophages/parasites and shows a dual effect. It
causes an apoptosis-like death in Leishmania parasites by generation of
reactive oxygen species, depletion of thiols, modulation of energy metabolism,
and by inhibition of DNA topoisomerases. Additionally in macrophages, it
induces a generation of reactive oxygen and nitrogen species by modulation of
mitogen-activated protein kinases. Initially, Sb(V) was used in a dose of 10 mg/
kg for 6–10 days, but increasing unresponsiveness in India led to successive
upward revisions, and currently the amount of drug being used is ten times
more than in previous years. Due to irregularity of use and poor patient
compliance, resistance against this drug has emerged. Increased presence of
drug efflux pumps and raised levels of non-protein thiols are the major
molecular mechanisms responsible for drug resistance in parasites. Owing to
high resistance, the usage of SAG is now restricted.
Solute carrier family 11A1 (SLC11A1): encoded by the SLC11A1 gene in
humans and is expressed in monocytes, macrophages, and neutrophils. It is an
integral phagolysosomal protein composed of 12 hydrophobic transmembrane
domains. Functionally, it acts as a divalent transition metal (iron and
manganese) transporter on the endosomal membrane and is involved in iron
metabolism and host resistance to certain pathogens. It was previously
referred to as natural resistance-associated macrophage protein 1 (NRAMP1).
Sterile cure: (radical cure) the complete or 100% elimination of the pathogen
from the host or organism. In a parasitic disease, sterile cure never happens.
Systemic memory response: attributable to the immune system mediated by
circulating memory T or B cells, whereby a second encounter with an antigen
induces a heightened state of immunity.
THP1 macrophage: a monocyte cell line derived from a patient diagnosed with
acute monocytic leukaemia. This cell line is grown in suspension and is a non-
adhesive type. Treating this cell line with PMA helps the cells to adhere and
differentiate into macrophages.
Tissue-specific immunity: the immune response specific to the tissue site. This
response is specific towards a specific antigen and is regulated by dendritic
cells, macrophages, T cells, and B cells.
T regulatory cells (Tregs): are a proportion of T cells usually identified by the
expression of the transcription factor FoxP3 and a high level of expression of
CD25. They can be either CD4+ or CD8+ and are important in controlling
heightened immune activation or inflammation. They act either through cell–
cell interaction such as cytotoxic T lymphocyte antigen 4 (CTLA-4) or by the
release of immunoregulatory cytokines such as IL-10 and TGF-b.
Tumour necrosis factor a (TNF-a): a strong mediator of inflammation, secreted
primarily from monocytes, macrophages, activated T and NK cells. Through
TNF receptors, it promotes cytotoxicity, induces angiogenesis, bone resorp-
tion, and thrombotic processes.
Urocanic acid: an intermediate of histidine catabolism with two isoforms of
which the trans form is the naturally occurring form. Trans-urocanic acid is
isomerised into the cis form by UVB light. Trans-urocanic acid acts as a natural
sunscreen, providing a low-level protection against UVB-induced DNA
damage. Cis-urocanic acid is proposed to have immunosuppressive properties
because it activates T regulatory cells, decreases the density of Langerhans
cells, and alters their morphology. In addition to its well-reported immuno-
suppressive properties, it can also initiate production of reactive oxygen
species and cause oxidative DNA damage.
Visceral leishmaniasis (VL) or kala-azar: is an infection of the reticuloendothe-
lial system, usually caused by the parasites L. donovani, Leishmania infantum,
or Leishmania chagasi. The majority of VL cases occur in Bangladesh, Brazil,
India, Nepal, and Sudan. It is the most fatal form of the leishmaniases if left
untreated. The patient presents with fever, malaise, and weight loss associated
with anaemia, hepatosplenomegaly, hypergammaglobulinemia, and conco-
mitant hypoalbuminemia.
Viscerotropic: the affinity or tendency of an organism to reside within viscera.
Vitamin D receptor (VDR): a nuclear receptor, which upon activation by
dihydroxylated vitamin D3, forms a heterodimer with retinoid X receptor (RXR)
and causes upregulation of arginase 1 and cathelicidin (LL-37), along with
subsequent downregulation of proinflammatory genes.
Vitamin D response elements (VDREs): a DNA sequence found in the promoter
region of vitamin D regulated genes. It is present in many cell types including
monocytes, macrophages, and dendritic cells. VDR, upon binding to dihy-
droxylated vitamin D3, enters into the nucleus and subsequently binds with
RXR; the resultant complex binds to VDREs to regulate gene expression, of
which the most potent is cathelicidin or LL-37.
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sections, we review key mechanisms suggested to be
involved in the development of PKDL.
A role for antimonial drugs
Epidemiological data and clinical reports have strongly
suggested a link between administration of sodiumantimony gluconate (SAG) and subsequent development
of PKDL [15]. In India, 62 out of 85 (73%) patients with
PKDL who were followed up for 9 years after cure from VL
were treated with SAG for VL [8]. A minority (23/85, 27%)
developed PKDL after being treated for VL with ampho-
tericin B (n = 13), ambisome (n = 2), miltefosine (n = 2),
miltefosine–amphotericin B (n = 1), or paromomycin
(n = 5), respectively. In Sudan, Bangladesh, and Nepal,
100% of PKDL patients received SAG [4–7], suggesting
that SAG could well influence the development of PKDL. A
small subgroup of 15–20% of patients with PKDL gave no
prior history of VL, attributable to subclinical infection and
had therefore not received any drug during that period
[8]. It is interesting, however, that SAG can and is still
being used for the treatment of PKDL, although at a higher
dose and for a prolonged period (20 mg/kg/day, intramus-
cular, for 4 months) than required for the treatment of VL
(20 mg/kg/day for 3 weeks). It is also plausible that differ-
ences in systemic versus skin concentrations of antileish-
manial drugs permit the survival of parasites in the latter.
However, before incriminating SAG for the development of
PKDL, further data are required on the frequency of PKDL
in cured VL patients treated with other more recently
introduced antileishmanial drug regimens. Due to the rise
in antimony resistance, there is now a long history of using
miltefosine and amphotericin B to treat patients with VL
in India [16]. As noted above, Thakur et al. reported that
using amphotericin B (20 mg/kg) for the treatment of VL
effectively minimised development of PKDL, whereas in
individuals treated with lower doses of amphotericin B
(15 mg/kg), PKDLwas reported [10]. Patients who received
miltefosine, paromomycin, and a combination therapy of
amphotericin B/miltefosine have rarely been found to de-
velop PKDL [17–19]. Collectively, available data strength-
ened the notion that SAG directly or indirectly influences
the incidence of PKDL, but definitive evidencemay require
another decade, because in India, PKDL can develop 20–40
years after cure fromVL [2,18]. Another speculation is that
antileishmanial drugs used at lower doses and for a shorter
duration eliminated parasites from the viscera, not from
the skin, which required a higher dose. Hence, PKDL
might not only be drug-related but could also result from
a dose-related phenomenon (Hypothesis 1). A more formal
understanding of drug pharmacokinetics/pharmacody-
namics is clearly warranted.
In addition to epidemiological evidence, immunological
data also support this hypothesis, because levels of immu-
noregulatory cytokines transforming growth factor b
(TGF-b) and interleukin 10 (IL-10), factors that support
parasite persistence, remained high even after completion
of treatment with SAG [20], whereas this was not the case
with amphotericin B or miltefosine [20,21]. Furthermore,
in an in vitromodel, treatment of THP1 macrophages with
SAG caused elevation of two anti-inflammatory, disease-
sustaining molecules, namely haem oxygenase 1 (HO-1)
and glutathione [22]. Another contributory factor is the
inability of SAG to restore the peroxisome function of the
host [23]. Additionally, the failure of SAG to provide a
sterile cure strongly indicates the possibility of drug-in-
duced genetic alterations in resistant parasites; SAG-re-
sistant parasites are proposed to have an enhanced degree67
Box 1. Immunology of PKDL
The precise immune mechanisms of PKDL are still obscure and,
interestingly, the immunobiology of the Sudanese and South
Asian PKDL differ. Therefore, information from one is not
extrapolatable to the other [2]. In Sudanese PKDL, because of
the shorter time lag between cure from VL and development of
PKDL, the disease-associated immune involvement mimics the
scenario of immune reactivation after cure from VL. PBMCs from
Sudanese PKDL patients react and proliferate following induction
by Leishmania antigens and secrete more IFN-g, whereas IL-10 was
produced primarily from CD4+ T cells [52]. By contrast, South Asian
PKDL is more chronic due to the longer gap between cure from VL
and disease onset. Here, CD8+ T cells predominated in lesions and
circulation [53,73]. Tregs also play an important role in the lesional
immunology of South Asian PKDL, as evident by their elevated
mRNA expression of FoxP3, CTLA-4, and CD25 [9,43]. In addition to
lesional immunology, systemic immune changes include in-
creased antigen-induced IL-10 within circulating CD8+ T cells and
impairment of antigen-induced proliferation. These cells were
anergic in nature because they lost their surface co-stimulatory
CD28 molecule [9,73]. Furthermore, the interacting partner of
CD28, known as B7.1 or CD86, on monocytes was decreased,
suggesting that an immunosuppressive milieu occurs in circula-
tion [21]. Lesional immunology of PKDL was similar in South Asian
and Sudanese PKDL with enhanced expression of IL-10, TGF-b,
IFN-g, and TNF-a. However, despite the higher levels of IFN-g and
TNF-a, the expression of IFN-gR and TNFR1 was lower in patients
with PKDL in India and increased after treatment [37,74]. Similarly,
in the Sudanese variant, a genetic polymorphism was found in
IFN-gR [63]. In Sudanese PKDL, expression of IL-10 from keratino-
cytes was considered as a key factor and a predictor for
development of PKDL, particularly after cure from VL [4]. Moreover,
the decreased presence of E-LCs plays a contributory role for
immune suppression. Recently, elevated levels of IL-17, its
transcription factor ROR-gt, and IL-22 in lesions and circulation
(plasma and lymphocytes) were reported [75]. Taken together,
immunological studies conducted so far indicate that PKDL is not a
localised disease, but involves systemic immunity. Figure 1 in
main text summarises our current knowledge of the local immune
response in patients with PKDL.
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PKDL-causing strains expressed higher levels of promasti-
gote surface antigen (PSA2) and glycoprotein 63 (gp63),
molecules associated with dermatotropism; concomitantly,
they had decreased expression of amastigote antigen 2 (A2),
which is linkedwith enhanced viscerotropism [25,26].Given
our recent understanding of the plasticity of theLeishmania
genome [27], and improved capacity and cost reductions
associatedwith parasite genome sequencing, future studies
aimed at characterising PKDL isolates with various drug
histories are now clearly essential and have become techni-
cally and financially achievable.
UV light contributes towards development of PKDL
Lesions of PKDL consistently appear on sun-exposed areas,
particularly the face, ears, arms, etc., rather thanunexposed
areas, such as the scalp and chest. This supports the concept
that exposure to UV light plays a contributory role in the
pathogenesis of PKDL (Hypothesis 2) (Figure 2) [28]. This
role of UV light is further highlighted by the characteristic
presence of photosensitivity in patients with PKDL. The
potent immunosuppressive property of UV light is linked to
its ability to damage the antigen presenting epidermal
Langerhans cells (E-LCs) and inhibit contact hypersensitiv-
ity and alloantigen responses [29].UVB light (280–320 nm)-
induced immunosuppression can operate either through its68chromophore cis-urocanic acid or via modulation of vita-
min D3 (Figure 2) [30,31]. During keratinisation, trans-
urocanic acid produced from histidine undergoes trans to
cis UV-induced photoisomerisation. All dermal cell types
are affected, especially E-LCs, wherein their numbers are
reduced and their morphology, particularly, the charac-
teristic dendritic pattern is altered; together, this attenu-
ates the antigen presenting property of dermal cells
[32,33]. These E-LCs from UV-irradiated skin have re-
duced expression of major histocompatibility complex
(MHC) class II, along with a loss of co-stimulatory mole-
cules, CD80 and CD86, which translates into impaired
antigen presentation (Figure 2) [34,35]. Additionally, by
exerting its influence on keratinocytes and lymphocytes,
cis-urocanic acid modulates a vast array of cytokines that
range from proinflammatory tumour necrosis factor a
(TNF-a) to anti-inflammatory and immunosuppressive
IL-10 [30]. In view of the fact that 40% of the adult
population are UVB sensitive, based on their impairment
of hapten-induced contact-dependent hypersensitivity,
this may also account for the low proportion of individuals
developing PKDL after cure from VL [28].
Studies on lesional patterns often mirror the clothing
habits of individuals, which strongly suggest a link be-
tween exposure to UV light and the pathogenicity of PKDL
[36]. However, no such study has been undertaken in India
but, notably, there is a consistent sparing of photoprotected
areas. Available data from Indian PKDL showed a down-
regulation of co-stimulatory molecules [21], similar to that
resulting from UV irradiation [30], and an increased ex-
pression of cytokines TNF-a and IL-10 at the lesional site
[37,38]. These data endorse a causal role for UV light in
both disease pathogenesis and immunosuppression.
UV, vitamin D3, and dihydroxylated vitamin D3
[1a,25(OH)2D3] have a potent immunomodulatory role
[31,39] in which UV light enhances the synthesis of vita-
min D3 (Figure 2). 7-Dehydrocholesterol absorbs UV light
and is converted into vitamin D3 by a series of enzymatic
and non-enzymatic reactions. The circulating vitamin D3
binds to vitaminD-binding protein (VBP) and subsequent-
ly enters immune cells, such as monocytes and macro-
phages. Within the cells upon further hydroxylation by a
mitochondrial enzymeCYP27B1, the active 1a,25(OH)2D3
is formed, which then forms a complex with vitamin D
receptor (VDR). The complex then translocates into the
nucleus, and after binding to the vitamin D response
elements (VDREs), induces synthesis of antibacterial pep-
tides and immunomodulatory factors, such as cathelicidin
(LL-37), TGF-b, and arginase [40,41]. The influence of
vitamin D3 on the immune system appears dichotomous.
On the one hand, it induces synthesis of potentially host-
protective antibacterial peptides from macrophages,
whereas on the other, it inhibits Toll-like receptor
(TLR)-induced activation of macrophages, downregulates
co-stimulatory molecules and proinflammatory cytokines,
and also induces TGF-b and IL-1. This ability to upreg-
ulate the arginase pathway implies that 1a,25(OH)2D3 or
vitamin D3 facilitates alternative activation of macro-
phages [42]. Additionally, the increased presence of regu-
latory T cells (Tregs) promotes IL-10 secretion, thereby
suppressing the local immune response and supporting
[(Figure_1)TD$FIG]
Figure 1. Current immunological scenario in Indian PKDL. Patients with Indian PKDL have distinct patterns of immunity in the skin and periphery. In the skin, immunity is
regulated by IL-10 and FoxP3 [9,43] because despite the enhanced levels of IFN-g and TNF-a, their respective receptors are downregulated [37,74]. Additionally, in the skin,
there is an increased presence of Th17 cells and IL-17 [75]. By contrast, peripheral immunity is controlled mostly by CD8+ T cells that are the major sources of IL-10 and are
anergic in nature [2,9]. Lack of co-stimulation was also evident because decreased CD28 and CD86 was found in circulating CD8+ T cells and CD14+ monocytes, respectively
[9,21]. Abbreviations: PKDL, post kala-azar dermal leishmaniasis; IL-10, interleukin 10; FoxP3, forkhead box P3; IFN-g, interferon g; TNF-a, tumour necrosis factor a; Th, T
helper.
Review Trends in Parasitology February 2014, Vol. 30, No. 2parasite persistence. In Indian PKDL, an increased pres-
ence of forkhead box P3 (FoxP3), a key molecular marker
of Tregs, has been reported [9,43]. Indeed, in B6.Vdr/
mice (which lack the gene encoding the vitamin D recep-
tor), resistance to Leishmania major infection is en-
hanced. Conversely, treatment of wild type mice with
1a,25(OH)2D3 led to a VDR-dependent inhibition of
macrophage killing, induction of arginase, and downre-
gulation of inducible nitric oxide synthase (iNOS) [44].
A strong case between exposure to UV and PKDL in
terms of dermal phenotypic changes exists, but does
not necessarily constitute an argument for causation.
Nevertheless, there is sufficient data to warrant
further exploration of the role of UV light in the aetio-
pathogenesis of PKDL, potentially feasible in animal
models. Alternatively, a metabolomic analysis to deter-
mine metabolites of the vitamin D3 pathway could
strengthen this hypothesis.
PKDL: a disease of reinfection or parasite persistence?
Ahallmark ofmany infectious diseases is persistence of the
pathogen after clinical cure, which occurs in tuberculosis,
viral infections (e.g., herpes), and protozoan diseases (e.g.,
trypanosomiasis) [45]. In leishmaniasis, evidence of para-
site persistence after clinical cure exists [46,47], and in
areas where leishmaniasis is endemic, recurrence has
been attributed to parasite persistence and/or reinfection
(Hypothesis 3). The optimal approach would be to charac-
terise these parasites and compare themwith the parentaltype, preferably using genomic and/or proteomic analysis.
This would establish whether the parasites were sourced
from the visceral form of the disease or after reinfection. In
a mouse model, parasites that persisted were genetically
similar to the parental clone [46]; however, analogous
studies in humans are logistically not possible, in view
of the parasite density being insufficient for establishment
of parasite isolates [45,47]. Because strains isolated from
individuals with VL and PKDL in India have genetic
heterogeneity [48], the axis tends to tilt in favour of rein-
fection. On the contrary, it can be hypothesised that para-
sites reside within an alternative cell type, such as
fibroblasts or keratinocytes, during the latency period
and, when reactivated, cause PKDL [25]. To address this
issue, parasites would need to be isolated from a patient
suffering from VL and compared with those isolated from
the very same individual when PKDL develops, which in
practical terms is very difficult owing to the long and
unpredictable lag period between VL and onset of PKDL.
However, such studies are feasible in Sudan where the
onset of PKDL following VL is much shorter [4]. In Sudan,
PKDL is probably due to parasite persistence because
patients cured of VL developed PKDL even after relocating
to an area where VL is not endemic (A.M. El Hassan et al.,
personal communication). Another challenge to the rein-
fection theory is why should genetically different strains
exclusively cause PKDL, and not re-emergence of VL? An
important factor possibly preventing reinfection could be
that VL generates a strong systemic memory response, but69
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Figure 2. Pathogenesis induced by UV light. UV light has a potential role in the pathogenesis of PKDL via enhanced secretion of cis-urocanic acid from keratinocytes and
vitamin D3. This translates into a reduced number of E-LCs, which also have an altered morphology [38]. In E-LCs, expression of MHCII, CD80, and CD86 are decreased, and
IL-10 is increased [9,38]. IL-4 secreted from Th2 cells subsequently activates dDCs to secrete more IL-10, which then induces an increased presence of Tregs, allowing for
parasite persistence. Similarly, TGF-b from infected macrophages can activate Tregs, which then produce more TGF-b, facilitating parasite persistence. Another possibility
is that raised levels of vitamin D3 polarise macrophages towards an alternatively activated phenotype that along with an enhanced presence of Tregs collectively generates
an immunosuppressive milieu. Abbreviations: PKDL, post kala-azar dermal leishmaniasis; dDC, dermal dendritic cell; E-LC, epidermal Langerhans cells; MHC, major
histocompatibility complex; IL-4, interleukin 4; IL-10, interleukin 10; Treg, T regulatory cell; TGF-b, tumour growth factor b; Th, T helper.
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parasites to multiply in the skin.
Failure of tissue-specific T cell memory
Recovery from Leishmania infection is often associated
with development of a strong memory immune response
that in humans confers lifelong protection against rein-
fection (Figure 3) [49]. However, under certain conditions,
such as immunosuppression, this infection-induced
immunity may be impaired, rendering the host suscepti-
ble to infection and/or reactivation of latent parasites
[50]. The diverse tissue microenvironments where para-
sites are found in VL, such as the liver and spleen,
qualitatively and quantitatively influence various
aspects of host immunity [51]. In this context, PKDL
poses an interesting challenge because despite acquisi-
tion of systemic protective immunity, apparent from the
recall cytokine or proliferative T cell responses measured
in peripheral blood mononuclear cells (PBMCs) or whole
blood assays [9,52], organ-specific immune deficits do
occur in the skin. This was evidenced by a local increase
of Tregs expressing the transcription factor FoxP3 and a
preponderance of CD8+ T cells [9,53] (Hypothesis 4,
Figure 3).70PKDL in Sudan and South Asia differ significantly in
terms of their disease outcome: in Sudanese PKDL, the
lesions regress spontaneously, whereas in South Asia,
prolonged treatment is essential [4]. This difference might
be correlated with the lag period of the disease, because in
Sudan patients develop PKDL with a much shorter lag
period or immediately after cure from VL and their immu-
nological responses might mimic post-VL features, that is,
active immune memory. In South Asia, there is a long lag
period and immunological responses differ significantly
and show immune anergy, that is, failure to elicit an
antigen-specific immune response [9].
Immune memory is a property of central memory (CM)
T cells (having a CD62Lhi, CD45RBhi, and CCR7hi pheno-
type) and effector memory (EM) T cells (having a
CD62Llow, CD45RBhi–low, and CCR7low phenotype) [49],
the latter beingmore functionally relevant than the former
[54]. However, in Indian PKDL due to the paucity of T
helper (Th) cells in the dermal lesions [53], the disease
acquires a non-self-healing nature. However, in Sudan, an
increased dermal presence of CD4+ T cells is associated
with self-healing PKDL. This concept would hold if com-
parative studies with the non-self-resolving Indian and
self-healing Sudanese PKDL showed different memory
[(Figure_3)TD$FIG]
Figure 3. Failure of organ-specific memory T cell response. Following infection with Leishmania parasites, individuals develop VL, and generally antileishmanial treatment
results in lifelong immunity due to the presence of systemic CM and EM T cells. In patients with self-limiting PKDL (e.g., in Sudan), an increased EM T cell response in the
skin causes spontaneous resolution. However, in Indian PKDL, a weak skin-specific EM T cell response accounts for its non-self-healing nature. Abbreviations: CM T cells,
central memory T cells; EM T cells, effector memory T cells; VL, visceral leishmaniasis; PKDL, post kala-azar dermal leishmaniasis.
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responses as measured by response to Leishmania antigen
or phytohaemagglutinin (PHA) stimulation in circulating
CD4+ T cells was intact, whereas CD8+ T cells were func-
tionally impaired [9]. Therefore, establishing the function-
al ability of these CD8+ memory T cells is necessary.
Another important factor that might play an important
role in the distinct pathology of Indian and Sudanese
PKDL is the expression of CD25 (the IL-2 receptor), pres-
ent on the regulatory T cell surface [43]. In Sudanese
PKDL, dermal biopsies showed a decreased presence of
CD25+ T cells [38], whereas in the Indian variant, cells
bearing CD25 were significantly increased [43].
For homing of memory CD4+ T cells, increased expres-
sion of the cutaneous lymphocyte antigen (CLA) is impor-
tant for self-resolution as observed in localised self-
resolving cutaneous leishmaniasis (CL), whereas the lack
of CLA expression in diffuse CL (DCL) correlates with a
non-healing outcome [55]. One can therefore envisage that
in PKDL, aberrant expression of CLA prevents CD4+ EMT
cells from homing to the dermal lesions. Granuloma for-
mation in the skin has been proposed to confer protection
against leishmaniasis as evidenced inCL [56]. Importantly,
in PKDL, granuloma formation is scanty and because
Indian PKDL is accompanied with a substantial decrease
in the proportion of CD4+ T cells [38,52,53,57], it strength-
ens the notion that impaired tissue-specific immunity
underpins disease persistence.
Host genetic susceptibility factors
All the factors discussed above have focused on
different aspects of host immunity, wound healing, andregeneration of the immune memory response, all of which
can potentially be regulated by the host genotype. Various
forms of leishmaniasis have been subjected to intense
genetic analysis in murine models and humans, but data
pertaining to patients with PKDL remain preliminary and
are restricted to three studies [58–61]. However, because
all three studies were performed in Sudan, the conundrum
remains unresolved as to why some but not all patients
with VL develop PKDL. A significant association between
interferon g receptor (IFN-gR polymorphism) and develop-
ment of PKDL has been reported (Hypothesis 5, Figure 4)
[62,63]. This was important because several studies have
reported an increased presence of both proinflammatory
and anti-inflammatory cytokines in the lesions
[9,37,52]. Polymorphisms in IFN-gR are associated with
its decreased functionality and expression that resulted in
decreased responsiveness, despite high levels of IFN-g.
Although a critical balance between IFN-g versus IL-4
and/or IL-10 secreting cells is essential in leishmaniasis
[64], no correlation was found between IFN-g or IL-10
promoter polymorphism and disease susceptibility
[63,65]. Furthermore, the failure to respond adequately
to IFN-g during active disease due to IFN-gR1 being
compromised would facilitate parasite growth and multi-
plication. Indeed, expression of IFN-gR1 is lower in indi-
viduals with Indian PKDL as compared with healthy
controls [37].
In Sudan, PKDL tends to develop in patients with VL
having higher levels of plasma C-reactive protein (CRP),
but the question remains as to whether genetic polymor-
phisms in CRP genes or their promoters correlate
with individuals having a higher propensity to develop71
Box 2. Outstanding questions
 Does treatment with sodium antimony gluconate cause any
epigenetic modifications of the host or parasites?
 Can any secondary skin infection lead to activation of latent
parasites?
 Can host nutritional factors such as trace elements influence the
strong systemic immunity in patients with PKDL?
 Are host/parasite genetic factors responsible for the differential
outcome of PKDL from South Asia versus East Africa?
 Is it possible to generate an animal model for PKDL using the
existing knowledge of genetic susceptibility and altered immune
pathology?
[(Figure_4)TD$FIG]
Figure 4. Genetic susceptibility of the host. A model indicating the possible interplay of genes that contributes towards host susceptibility in PKDL. SLC11A1 enhances
macrophage activation in terms of its antimicrobial activity (e.g., iron sequestration from parasites) [72]. Polymorphisms of SLC11A1 (SLC11A1lo) can render the host
susceptible to VL; additionally, in these individuals, a polymorphism in the IFN-gR gene (IFN-gRlo) makes them more susceptible to developing PKDL, owing to the reduced
functionality of the IFN-gR gene. Tregs secrete both IL-10 and IFN-g, but due to the decreased activity of IFN-gR, the immune deactivating properties of IL-10 predominate;
conversely, IFN-gRhi individuals are cured of VL and are less prone to develop PKDL. Abbreviations: Mf, macrophage; SLC11A1, solute carrier family 11A1; IFN-gR,
interferon g receptor; IL-10R, interleukin 10 receptor; Treg, T regulatory cell; VL, visceral leishmaniasis; PKDL, post kala-azar dermal leishmaniasis.
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larly those associated with complement activation, such
as FCN-2 (encoding Ficolin-2), are associated with an
enhanced susceptibility to CL [67,68]. Polymorphisms at
the promoter regions of the FCN-2 gene are associated
with its decreased expression and increased susceptibili-
ty to CL [68]. The increased expression of mannose-
binding lectin 2 (MBL2) was stated to be associated with
VL and, indeed, increased serum levels of MBL2 and
genetic polymorphism at the promoter and exons of
MBL2 correlated with disease susceptibility [69]. Anoth-
er important candidate gene for leishmaniasis is
SLC11A1 (formerly known as NRAMP1), which encodes
the solute carrier family 11a (SLC11A1). SLC11A1 func-
tions as a proton/divalent cation antiporter present on
the endosomal membrane of phagocytes. SLC11A1 has
diverse effects on macrophage activation, including reg-
ulation of IL-1b, iNOS, MHC class II molecules, TNF-a,
nitric oxide (NO) release, oxidative burst, and antimi-
crobial activity [70]. Polymorphisms of SLC11A1 at the
promoter and exons make it functionally null and are
associated with increased susceptibility to VL (Figure 4)
[71,72]. The lack of studies with PKDL emphasises the
need to establish susceptibility determinants. Addition-
ally, it can be envisaged that investigation of epigenetic
modification(s) in the aforementioned genes would help
establish the underlying cause(s) for development of
PKDL.72Concluding remarks
PKDL is a perplexing disease, in particular for the shift in
parasite tropism after the onset of apparent cure from VL
and for the geographical variation in clinical presentation.
The factors discussed above provide suitable explanations
for PKDL, at least in some geographical settings. The lack
of mouse models of PKDL precludes formal testing of some
of these hypotheses but they have helped focus attention on
how best to analyse the available clinical material. Thus, it
can be concluded that development of PKDL is multifacto-
rial and one/more of the hypotheses discussed above have a
contributory role on the development of the disease, and
future research should aim to address the several unan-
swered yet relevant questions (Box 2). Studies of parasite
genotypes and phenotypes are clearly a high priority and
Review Trends in Parasitology February 2014, Vol. 30, No. 2need to be intimately linked to state-of-the-art functional
histopathology, including, for example, tissue-based tran-
scriptomics. In years to come, creative clinical studies on
this challenging disease merged with the application of the
latest ‘omics’ approaches are sure to yield new insights into
the complexity of the Leishmania–host interaction and
open new doors for disease control.
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